Anodyne Nanotech Raises $12.6M in Series A Funding Round

The company plans to use the funding to expand manufacturing, advance ANN-101—its once-weekly GLP-1 patch for obesity—into Phase I clinical trials, and speed up development of its transdermal drug delivery platform for peptides, antibodies, and nucleic acid therapies.

Anodyne has appointed Vikram Lamba to its Board of Directors. He brings more than 30 years of leadership and business development experience from both global pharmaceutical companies and biotechnology startups.

Read More:CentSight Raises $1.5M in Pre-Seed Funding Round

Lamba previously served as CEO of Zosano Pharma, where he led a $425 million partnership with Eli Lilly focused on microneedle technology and helped take the company public. Earlier in his career, he held senior mergers, acquisitions, and corporate development roles at Bayer AG, including serving as Director of M&A.

“Anodyne is building the delivery layer for the next generation of complex medicines,” said George Papastergiou, Partner at Velocity Partners VC. “Biologic drugs are still delivered via injections, creating friction for patients and limiting adherence, especially in chronic conditions. Anodyne’s needle-free transdermal platform is designed to deliver injectable-grade performance with tunable pharmacokinetics, enabling more effective and patient-friendly therapies with fewer side effects.

“This financing marks a significant milestone for Anodyne,” said Jake Lombardo, Chief Executive Officer of Anodyne Nanotech. “Our lead program, ANN-101, addresses significant unmet needs in a disease rapidly coming to the forefront of healthcare. We have demonstrated the ability to deliver multi-milligram weekly doses of a GLP-1 with a patch, and reach the exposures obesity treatment requires, without an injection or cold storage. The platform’s defining ability to deliver large doses enables co-formulation and delivery of multiple active ingredients in a single patch.

About Anodyne Nanotech

Founded in 2019 by Jake Lombardo, Konstantinos Tzortzakis, and Hojat Rezaei Nejad, Anodyne Nanotech is a biotechnology company developing advanced transdermal drug delivery technologies. Its microneedle patch technology is designed to deliver peptides, antibodies, and nucleic acid therapies through a simple, room-temperature-stable patch while providing effectiveness similar to injections. The company's lead product, ANN-101, is a once-weekly GLP-1 patch for obesity treatment.

Read More:Seltz Raises $12.5M in Seed Funding Led by B Capital